Cardiff Oncology, Inc. (NASDAQ:CRDF – Free Report) – Equities research analysts at HC Wainwright raised their FY2026 earnings per share estimates for Cardiff Oncology in a research report issued on Monday, November 16th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.55) per share for the year, up from their prior forecast of ($0.56). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for Cardiff Oncology’s Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.29) EPS.
Cardiff Oncology (NASDAQ:CRDF – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. The company had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.08 million. Cardiff Oncology had a negative return on equity of 111.80% and a negative net margin of 6,736.49%.
Get Our Latest Stock Analysis on CRDF
Cardiff Oncology Stock Up 5.1%
Shares of NASDAQ CRDF opened at $0.88 on Wednesday. The firm’s 50-day moving average price is $1.02 and its 200-day moving average price is $1.33. Cardiff Oncology has a 52-week low of $0.71 and a 52-week high of $3.31.
Institutional Investors Weigh In On Cardiff Oncology
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Cardiff Oncology in the second quarter worth approximately $1,265,000. GoalVest Advisory LLC purchased a new stake in shares of Cardiff Oncology in the third quarter worth $832,000. Flputnam Investment Management Co. purchased a new stake in shares of Cardiff Oncology in the second quarter worth $322,000. X Square Capital LLC bought a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $267,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $225,000. Institutional investors own 16.29% of the company’s stock.
About Cardiff Oncology
Cardiff Oncology is a clinical-stage biotechnology company focused on developing cancer treatments. Its lead drug candidate, onvansertib, is an oral, selective inhibitor of polo-like kinase 1 (PLK1), a protein involved in cell division that the company is investigating as a target in cancer therapy. The company is studying onvansertib in combination with existing treatments for several cancers, including metastatic colorectal cancer and acute myeloid leukemia. These programs remain in clinical development, and the candidate is not an approved treatment.
Read More
- Five stocks we like better than Cardiff Oncology
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
